A human model of inflammatory cardio-metabolic dysfunction; a double blind placebo-controlled crossover trial
BACKGROUND: Chronic inflammation may contribute to insulin resistance (IR), metabolic syndrome and atherosclerosis although evidence of causality is lacking in humans. We hypothesized that very low-dose experimental endotoxemia would induce adipose tissue inflammation and systemic IR during a low-gr...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3477112/ https://www.ncbi.nlm.nih.gov/pubmed/22709547 http://dx.doi.org/10.1186/1479-5876-10-124 |
_version_ | 1782247192296161280 |
---|---|
author | Mehta, Nehal N Heffron, Sean P Patel, Parth N Ferguson, Jane Shah, Rachana D Hinkle, Christine C Krishnamoorthy, Parasuram Shah, Rhia Tabita-Martinez, Jennifer Terembula, Karen Master, Stephen R Rickels, Michael R Reilly, Muredach P |
author_facet | Mehta, Nehal N Heffron, Sean P Patel, Parth N Ferguson, Jane Shah, Rachana D Hinkle, Christine C Krishnamoorthy, Parasuram Shah, Rhia Tabita-Martinez, Jennifer Terembula, Karen Master, Stephen R Rickels, Michael R Reilly, Muredach P |
author_sort | Mehta, Nehal N |
collection | PubMed |
description | BACKGROUND: Chronic inflammation may contribute to insulin resistance (IR), metabolic syndrome and atherosclerosis although evidence of causality is lacking in humans. We hypothesized that very low-dose experimental endotoxemia would induce adipose tissue inflammation and systemic IR during a low-grade but asymptomatic inflammatory response and thus provide an experimental model for future tests of pharmacologic and genomic modulation of cardio-metabolic traits in humans. METHODS: Ten healthy, human volunteers (50% male, 90% Caucasian, mean age 22.7 ± 3.8) were randomized in a double-masked, placebo-controlled, crossover study to separate 36-hour inpatient visits (placebo versus intravenous-LPS 0.6 ng/kg). We measured clinical symptoms via the McGill pain questionnaire and serial vital signs. Plasma and serum were collected for measurement of cytokines, C-reactive protein, insulin and glucose, serial whole blood & subcutaneous adipose tissue mRNA expression were measured by real-time PCR. HOMA-IR, a well-validated measure of IR was calculated to estimate insulin resistance, and frequently sampled intravenous glucose tolerance testing (FSIGTT) was performed to confirm an insulin resistant state. We performed ANOVA and within subject ANOVA to understand the differences in cytokines, adipose tissue inflammation and IR before and after LPS or placebo. RESULTS: There was no significant difference between placebo and LPS in clinical responses of symptom scores, body temperature or heart rate. However, low-dose endotoxemia induced a rapid and transient 25-fold induction of plasma TNF-alpha and 100-fold increase in plasma IL-6 (Figure 1B) (p < 0.001 for both) both peaking at two hours, followed by modest inflammation in adipose tissue with increases in mRNA levels of several inflammatory genes known to modulate adipose and systemic insulin resistance. Adipose tissue mRNA levels of IL-6 (peak 6-fold, ANOVA F = 27.5, p < 0.001) and TNF-alpha (peak 1.8-fold, F = 2.9, p = 0.01) increased with MCP-1 (peak 10-fold, F = 5.6, p < 0.01) and fractalkine (CX3CL1) (peak 15-fold, F = 13.3, p < 0.001). Finally, HOMA-IR was 32% higher following LPS compared to placebo (p < 0.01) and insulin sensitivity declined by 21% following LPS compared to placebo (p < 0.05). CONCLUSIONS: We present a low dose human endotoxemia model of inflammation which induces adipose tissue inflammation and systemic insulin resistance in the absence of overt clinical response. Such a model has the potential for broad and safe application in the study of novel therapeutics and genomic influences in cardio-metabolic disease. |
format | Online Article Text |
id | pubmed-3477112 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2012 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-34771122012-10-20 A human model of inflammatory cardio-metabolic dysfunction; a double blind placebo-controlled crossover trial Mehta, Nehal N Heffron, Sean P Patel, Parth N Ferguson, Jane Shah, Rachana D Hinkle, Christine C Krishnamoorthy, Parasuram Shah, Rhia Tabita-Martinez, Jennifer Terembula, Karen Master, Stephen R Rickels, Michael R Reilly, Muredach P J Transl Med Research BACKGROUND: Chronic inflammation may contribute to insulin resistance (IR), metabolic syndrome and atherosclerosis although evidence of causality is lacking in humans. We hypothesized that very low-dose experimental endotoxemia would induce adipose tissue inflammation and systemic IR during a low-grade but asymptomatic inflammatory response and thus provide an experimental model for future tests of pharmacologic and genomic modulation of cardio-metabolic traits in humans. METHODS: Ten healthy, human volunteers (50% male, 90% Caucasian, mean age 22.7 ± 3.8) were randomized in a double-masked, placebo-controlled, crossover study to separate 36-hour inpatient visits (placebo versus intravenous-LPS 0.6 ng/kg). We measured clinical symptoms via the McGill pain questionnaire and serial vital signs. Plasma and serum were collected for measurement of cytokines, C-reactive protein, insulin and glucose, serial whole blood & subcutaneous adipose tissue mRNA expression were measured by real-time PCR. HOMA-IR, a well-validated measure of IR was calculated to estimate insulin resistance, and frequently sampled intravenous glucose tolerance testing (FSIGTT) was performed to confirm an insulin resistant state. We performed ANOVA and within subject ANOVA to understand the differences in cytokines, adipose tissue inflammation and IR before and after LPS or placebo. RESULTS: There was no significant difference between placebo and LPS in clinical responses of symptom scores, body temperature or heart rate. However, low-dose endotoxemia induced a rapid and transient 25-fold induction of plasma TNF-alpha and 100-fold increase in plasma IL-6 (Figure 1B) (p < 0.001 for both) both peaking at two hours, followed by modest inflammation in adipose tissue with increases in mRNA levels of several inflammatory genes known to modulate adipose and systemic insulin resistance. Adipose tissue mRNA levels of IL-6 (peak 6-fold, ANOVA F = 27.5, p < 0.001) and TNF-alpha (peak 1.8-fold, F = 2.9, p = 0.01) increased with MCP-1 (peak 10-fold, F = 5.6, p < 0.01) and fractalkine (CX3CL1) (peak 15-fold, F = 13.3, p < 0.001). Finally, HOMA-IR was 32% higher following LPS compared to placebo (p < 0.01) and insulin sensitivity declined by 21% following LPS compared to placebo (p < 0.05). CONCLUSIONS: We present a low dose human endotoxemia model of inflammation which induces adipose tissue inflammation and systemic insulin resistance in the absence of overt clinical response. Such a model has the potential for broad and safe application in the study of novel therapeutics and genomic influences in cardio-metabolic disease. BioMed Central 2012-06-18 /pmc/articles/PMC3477112/ /pubmed/22709547 http://dx.doi.org/10.1186/1479-5876-10-124 Text en Copyright ©2012 Mehta et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Mehta, Nehal N Heffron, Sean P Patel, Parth N Ferguson, Jane Shah, Rachana D Hinkle, Christine C Krishnamoorthy, Parasuram Shah, Rhia Tabita-Martinez, Jennifer Terembula, Karen Master, Stephen R Rickels, Michael R Reilly, Muredach P A human model of inflammatory cardio-metabolic dysfunction; a double blind placebo-controlled crossover trial |
title | A human model of inflammatory cardio-metabolic dysfunction; a double blind placebo-controlled crossover trial |
title_full | A human model of inflammatory cardio-metabolic dysfunction; a double blind placebo-controlled crossover trial |
title_fullStr | A human model of inflammatory cardio-metabolic dysfunction; a double blind placebo-controlled crossover trial |
title_full_unstemmed | A human model of inflammatory cardio-metabolic dysfunction; a double blind placebo-controlled crossover trial |
title_short | A human model of inflammatory cardio-metabolic dysfunction; a double blind placebo-controlled crossover trial |
title_sort | human model of inflammatory cardio-metabolic dysfunction; a double blind placebo-controlled crossover trial |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3477112/ https://www.ncbi.nlm.nih.gov/pubmed/22709547 http://dx.doi.org/10.1186/1479-5876-10-124 |
work_keys_str_mv | AT mehtanehaln ahumanmodelofinflammatorycardiometabolicdysfunctionadoubleblindplacebocontrolledcrossovertrial AT heffronseanp ahumanmodelofinflammatorycardiometabolicdysfunctionadoubleblindplacebocontrolledcrossovertrial AT patelparthn ahumanmodelofinflammatorycardiometabolicdysfunctionadoubleblindplacebocontrolledcrossovertrial AT fergusonjane ahumanmodelofinflammatorycardiometabolicdysfunctionadoubleblindplacebocontrolledcrossovertrial AT shahrachanad ahumanmodelofinflammatorycardiometabolicdysfunctionadoubleblindplacebocontrolledcrossovertrial AT hinklechristinec ahumanmodelofinflammatorycardiometabolicdysfunctionadoubleblindplacebocontrolledcrossovertrial AT krishnamoorthyparasuram ahumanmodelofinflammatorycardiometabolicdysfunctionadoubleblindplacebocontrolledcrossovertrial AT shahrhia ahumanmodelofinflammatorycardiometabolicdysfunctionadoubleblindplacebocontrolledcrossovertrial AT tabitamartinezjennifer ahumanmodelofinflammatorycardiometabolicdysfunctionadoubleblindplacebocontrolledcrossovertrial AT terembulakaren ahumanmodelofinflammatorycardiometabolicdysfunctionadoubleblindplacebocontrolledcrossovertrial AT masterstephenr ahumanmodelofinflammatorycardiometabolicdysfunctionadoubleblindplacebocontrolledcrossovertrial AT rickelsmichaelr ahumanmodelofinflammatorycardiometabolicdysfunctionadoubleblindplacebocontrolledcrossovertrial AT reillymuredachp ahumanmodelofinflammatorycardiometabolicdysfunctionadoubleblindplacebocontrolledcrossovertrial AT mehtanehaln humanmodelofinflammatorycardiometabolicdysfunctionadoubleblindplacebocontrolledcrossovertrial AT heffronseanp humanmodelofinflammatorycardiometabolicdysfunctionadoubleblindplacebocontrolledcrossovertrial AT patelparthn humanmodelofinflammatorycardiometabolicdysfunctionadoubleblindplacebocontrolledcrossovertrial AT fergusonjane humanmodelofinflammatorycardiometabolicdysfunctionadoubleblindplacebocontrolledcrossovertrial AT shahrachanad humanmodelofinflammatorycardiometabolicdysfunctionadoubleblindplacebocontrolledcrossovertrial AT hinklechristinec humanmodelofinflammatorycardiometabolicdysfunctionadoubleblindplacebocontrolledcrossovertrial AT krishnamoorthyparasuram humanmodelofinflammatorycardiometabolicdysfunctionadoubleblindplacebocontrolledcrossovertrial AT shahrhia humanmodelofinflammatorycardiometabolicdysfunctionadoubleblindplacebocontrolledcrossovertrial AT tabitamartinezjennifer humanmodelofinflammatorycardiometabolicdysfunctionadoubleblindplacebocontrolledcrossovertrial AT terembulakaren humanmodelofinflammatorycardiometabolicdysfunctionadoubleblindplacebocontrolledcrossovertrial AT masterstephenr humanmodelofinflammatorycardiometabolicdysfunctionadoubleblindplacebocontrolledcrossovertrial AT rickelsmichaelr humanmodelofinflammatorycardiometabolicdysfunctionadoubleblindplacebocontrolledcrossovertrial AT reillymuredachp humanmodelofinflammatorycardiometabolicdysfunctionadoubleblindplacebocontrolledcrossovertrial |